Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Article: The Patient Abroad

April 2, 2015 |  

Published in Medical Marketing & Media March 2015

Approximately 11 million people were medical tourists in 2013, generating a market worth over $50 billion. While obtaining accurate data is challenging, estimates suggest the global medical tourism market is expanding by 25% each year.

Having grown up in the UK, where high-quality healthcare is available to all through the National Health Service, I hadn’t given the concept of medical tourism a great deal of thought before I moved to Asia. It would simply not have occurred to me to seek healthcare overseas for any other reason than if I happened to fall ill while traveling. 

I first became aware of the concept when reading rumors that Zimbabwe’s President Robert Mugabe was being treated in one of Singapore’s exclusive private hospitals – which happened to be just down the road from my apartment at the time. This led to much discussion among my peers about how much it would cost to be a medical tourist in Singapore. “High end” patients can expect to accrue bills of thousands of dollars. The most expensive “hospitel” (hospital hotel) penthouse suite (not room) in Singapore costs over $8,000 per night – and it does not include the additional costs of medical treatment. This particular establishment anticipates that at least half of its “guests” (not patients) will come from overseas.

Read the full article on Medical Marketing & Media »

This content was provided by Inizio

Company Details

- PMLiVE

Inizio

Email
Website

 Latest Content from  Inizio 

Video: Self-pay and Emerging Markets

A key feature of emerging markets is that patients often have to pay for a high proportion of their healthcare costs themselves. For all but the most severe conditions, public...

News: Therapy Watch HCV expands into 4 additional EU markets

The HCV market has been growing and changing remarkably quickly and with the development of new and improving drugs, the treatment of HCV has moved on in a short space...

News: Research Partnership launches new patient report – Living with Ulcerative Colitis

Living with UC is a quantitative study conducted online amongst 325 patients, including both adult and paediatric patients diagnosed with ulcerative colitis in 5 EU markets (France, Germany, Italy, Spain...

Summer Intern experience at Research Partnership

We look for bright and inquisitive people who want to learn in a company that's pushing the boundaries of pharmaceutical market research

Double win at Communiqué 2016: Pegasus scoops awards for Consultancy of the Year (for the second time!) and Excellence in Media Relations

Pegasus, an Ashfield company, part of UDG Healthcare plc, is delighted to have won the prestigious Consultancy of the Year award at the 2016 Communiqué Awards in London. The judges...

Beyond Andrology: Trends in Men’s Health in Emerging Markets

Published in eyeforpharma July 2016 by Rachel Howard

Pharma & life sciences division growth allows Pegasus to fill three new senior positions

Pegasus has expanded its pharma & life sciences senior team by appointing a new Associate Director and promoting two members of the existing team to Account Directors.

Infographic: HIV Market Snapshot

Our latest HIV infographic, taken from data collected from syndicated tracking study Therapy Watch, reveals that more than 3 in 5 naive or switch patients are currently treated with a STR (single...

Infographic: The vaccine opportunity in Asia

As predicted, the vaccine market in emerging and developing countries has continued to expand. While the global vaccine market is expected to grow at around 12% annually over the next...

Webinar: What next for biosimilars?

Tuesday 19th July 15:00 BST/10:00 EDT/16:00 CEST